• Users Online:237
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2022  |  Volume : 11  |  Issue : 5  |  Page : 371-376

Safety and efficacy of EUS-guided ablation of pancreatic lesions with ethanol versus ethanol with paclitaxel: A systematic review and meta-analysis

1 Department of Internal Medicine, University of Nevada Las Vegas School of Medicine, Las Vegas, Nevada, USA
2 Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA
3 Department of Internal Medicine, New York Medical College, NYC Health + Hospitals/Metropolitan, New York, NY, USA
4 Division of Gastroenterology and Hepatology, Moffitt Cancer Center, Tampa, FL, USA
5 Department of Biostatistics, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA
6 Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, New York, USA
7 Division of Gastroenterology and Hepatology, CHI Health Creighton University Medical Center, Omaha, NE, USA
8 Division of Gastroenterology and Hepatology, University of Utah, Salt Lake City, Utah, USA
9 Center for Advanced Therapeutic Endoscopy (CATE), Centura Health, Porter Hospital, Peak Gastroenterology, Denver, Colorado, USA

Correspondence Address:
Dr. Douglas G Adler
Porter Adventist Hospital 2525 S Downing St, Denver, CO 80210
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/EUS-D-20-00185

Rights and Permissions

Background and Objectives: EUS-guided ethanol ablation has emerged as an alternative method for pancreatic lesions. Recently, paclitaxel was added to ethanol to assess ablative effects in pancreatic lesions. We performed a systematic review and meta-analysis on EUS-guided ethanol ablation (EUS E) versus EUS-guided ethanol with paclitaxel (EUS EP) ablation for the management of pancreatic lesions. Methods: Comprehensive search of multiple electronic databases and conference proceedings including PubMed, EMBASE, Google Scholar, and Web of Science databases (from inception to May 2020). The primary outcome evaluated complete ablation of the lesions radiologically and the secondary outcome evaluated adverse events (AEs). Results: Fifteen studies on 524 patients were included in our analysis. The pooled complete ablation rate was 58.89% (95% confidence interval (CI) = 38.72–77.80, I2 = 91.76%) and 55.99% (95% CI = 44.66–67.05, I2 = 0) in the EUS E and EUS EP groups (P = 0.796), respectively. The pooled AE rates were 13.92% (95% CI = 4.71–26.01, I2 = 83.43%) and 31.62% (95% CI = 3.36–68.95, I2 = 87.9%) in the EUS E and EUS EP groups (P = 0.299), respectively. The most common AE was abdominal pain at 7.27% (95% CI = 1.97–14.6, I2 = 68.2%) and 12.44% (95% CI = 0.00–39.24, I2 = 81.1%) in the EUS E and EUS EP groups (P = 0.583), respectively. Correlation coefficient (r) was ‒0.719 (P = 0.008) between complete ablation and lesion size. Conclusion: Complete ablation rates were comparable among both groups. AE rates were higher in the EUS EP group. Further randomized controlled trials are needed to validate our findings.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded187    
    Comments [Add]    

Recommend this journal